SMS Pharmaceuticals Limited
SMSPHARMA · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹318.23.
Piotroski F-score 5/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%14.3%
- ✓Low debt (D/E < 0.5)0.46x
- ✕Positive free cash flow
- ✕Revenue growth > 10%-4%
- ✓Earnings growing49%
- ✓Net margin ≥ 10%11.5%
- ✓Current ratio > 1.51.81
- ✓Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✕Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 4.31
- ✕Piotroski ≥ 75/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Financially solid — Altman Z 4.31.
Opportunities
- •Earnings growing (49% YoY).
About SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and its intermediates in India and internationally. It offers anti-retroviral, anti-inflammatory, anti-viral, anti-diabetic, anti-fungal, anti-epileptic, anti-migraine, anti-coagulant, anti-psychotic, anti-aginal, and anti-ulcer products. It is also involved in contract research activities on peptides
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.